GRAL GRAIL, LLC
Company Analysis
Latest News
🟢 GRAIL is trading 5.85% up today after FDA panel backed Galleri’s benefit-risk profile
GRAIL is trading 5.85% up at $114.87 after an FDA advisory panel supported Galleri’s benefit-risk profile for approval on September 23, 2026. - The panel...
🔴 GRAIL is trading 6.5% down in pre-market after investors reassess a mixed FDA panel vote
GRAIL is trading at $101.50, down 6.47%, as investors reassess the mixed September 23, 2026 FDA advisory-panel recommendation. - The panel backed Galleri’s...
🟢 GRAIL is trading 7.6% up in pre-market after FDA panel favored Galleri approval
GRAIL is trading at $116.80, up +7.6%, after a favorable September 23 FDA advisory-panel vote supporting Galleri’s approval. - The panel voted 7–2, with one...
🟢 GRAIL rises 4.2% — Biotech Sector Rallies on Major AI Collaboration Deal and Positive Clinical News
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is trading higher, driven by a...
🟢 GRAIL is trading 17.6% up today ahead of September 23 FDA advisory committee review
GRAIL is trading at $95.00, +17.62% (17.6% up) after investors positioned ahead of the September 23 FDA advisory committee review of Galleri’s premarket...
GRAIL Surges 15% as Investors Bet Big on an FDA Panel That Could Make or Break the Blood-Test Cancer Screener — But Is the Market Pricing in a Win It Hasn't Earned?
Shares of GRAIL (GRAL) rocketed 14.6% to $92.60 Monday, capping a weeklong climb from $75.53, as traders placed aggressive bets ahead of a make-or-break...
🟢 GRAIL is trading 14.65% up in pre-market ahead of September 23 FDA Galleri review
GRAIL is trading 14.65% up now at $92.60, with the strongest catalyst appearing to be the FDA advisory committee meeting scheduled for September 23, 2026, to...
🟢 GRAIL rises 5.0% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
GRAIL earns UBS strong buy rating, ahead of key FDA cancer review
UBS Group upgraded GRAIL, LLC to a strong-buy rating on September 12, 2026. The upgrade follows the company's August 5 earnings report. GRAIL reported a...
Manufacturers Life Buys GRAIL Stake, Eyeing 2027 Cancer Test Approval
Manufacturers Life Insurance Company acquired 21,597 shares of GRAIL, Inc. during the second quarter. The new stake is valued at approximately $1.474 million...
🔴 GRAIL is trading 4.15% down today with no clear company-specific catalyst
GRAIL is trading at $76.68, down -4.15%, with no clear company-specific catalyst directly explaining the decline. • No new GRAIL announcement dated August 31,...
🔴 GRAIL falls 4.3% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
Casdin Capital more than doubles its stake in cancer detection firm GRAIL (GRAL)
Life sciences investor Casdin Capital significantly increased its position in early cancer detection company GRAIL (GRAL), more than doubling its share count...
🟢 GRAIL is trading 4.24% up in after-hours trading amid stronger technology sentiment after Nvidia and Salesforce results
GRAIL is trading 4.24% up in after-hours trading at $86.00, primarily aligned with stronger broader-market and technology sentiment following Nvidia and...
🟢 GRAIL is trading 4.55% up today
GRAIL is trading 4.55% up now at $83.21 after a volatile week, with no clear company-specific catalyst identified for August 27, 2026. - Latest disclosed...
🔴 GRAIL is trading 4.6% down today with no clear company-specific catalyst
GRAIL is trading 4.6% down now at $78.75, with no clear company-specific announcement identified to explain the decline. - Shares rose 7.78% to $82.54 on...
🟢 GRAIL rises 5.3% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
GRAIL Faces Misconduct Probe, Following Failed NHS-Galleri Cancer Trial
A law firm is investigating GRAIL, Inc. officers and directors for potential wrongdoing on behalf of long-term investors. This probe follows a lawsuit alleging...
🟢 GRAIL is trading 5% up today
GRAIL is trading 5.3% up at $77.88, with no clear company-specific catalyst identified for August 20, 2026. - The latest material development is the FDA’s...
🟢 GRAIL is trading 4.8% up today as immediate catalyst remains unclear
GRAIL is trading 4.8% up at $77.48, while the immediate catalyst remains unclear. - No new company-specific announcement dated August 20, 2026, was identified...